ArticleScientific reports2016
Manipulating the Biosynthesis of Bioactive Compound Alkaloids for Next-Generation Metabolic Engineering in Opium Poppy Using CRISPR-Cas 9 Genome Editing Technology.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 239 citations in OpenAlex.
- Next-Generation Metabolic Engineering of Capsaicinoids Biosynthesis in Chilli Pepper: Bridging Genomic Insights to Biotechnological Applications.Biotech (Basel (Switzerland)) · 2026Review
- Advances in molecular breeding of medicinal plants.Molecular horticulture · 2026Review
- Advances in Functional Genomics and Biotechnology for Enhancing Therapeutic Potential of Medicinal Plants.International journal of molecular sciences · 2026Review
- Virus-induced genome editing enables functional genomics across diverse plant species.Molecules and cells · 2026Review
- A Rapid Hairy Root-Based Platform for CRISPR/Cas Optimization and Guide RNA Validation in Lettuce.Plants (Basel, Switzerland) · 2026Article
- Synthetic Biology of Plants and Microbes for Agriculture, Environment, and Future Applications.Chemical reviews · 2026Review
- Transport of secondary metabolites in plants: Mechanistic insights and transporter engineering for crop improvement.Plant communications · 2025Review
- Biotechnological Advances in Sanguinarine and Chelerythrine Production from Plume Poppy (Plants (Basel, Switzerland) · 2025Review
- Complexity Meets Risk-The Next Generation of Genome-Edited Plants Challenges Established Concepts for Environmental Risk Assessment in the EU.Plants (Basel, Switzerland) · 2025Review
- Highly efficient Agrobacterium rhizogenes-mediated gene editing system in Salvia miltiorrhiza inbred line bh2-7.Plant biotechnology journal · 2025Article
- Modification of Gene Expression Involved in Alkaloid Production in Opium Poppy by VIGS Combined With Pretreatment of Macerozyme Enzyme.Plant direct · 2025Article
- Integration of CRISPR/Cas9 with multi-omics technologies to engineer secondary metabolite productions in medicinal plant: Challenges and Prospects.Functional & integrative genomics · 2024Review
- Herbgenomics meets Papaveraceae: a promising -omics perspective on medicinal plant research.Briefings in functional genomics · 2024Review
- Developing benzylisoquinoline alkaloid-enriched opium poppy via CRISPR-directed genome editing: A review.BMC plant biology · 2024Review
- A high-efficient protoplast transient system for screening gene editing elements in Salvia miltiorrhiza.Plant cell reports · 2024Article
- Enhancement of specialized metabolites using CRISPR/Cas gene editing technology in medicinal plants.Frontiers in plant science · 2024Review
- Application and development of CRISPR technology in the secondary metabolic pathway of the active ingredients of phytopharmaceuticals.Frontiers in plant science · 2024Review
- The potential of genome editing to create novel alleles of resistance genes in rice.Frontiers in genome editing · 2024Review
- Promising approaches for simultaneous enhancement of medicinally significant benzylisoquinoline alkaloids in opium poppy.Frontiers in plant science · 2024Review
- Development of virus-induced genome editing methods in Solanaceous crops.Horticulture research · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated9 (Cas9) endonuclease system is a powerful RNA-guided genome editing tool. CRISPR/Cas9 has been well studied in model plant species for targeted genome editing. However, few studies have been reported on plant species without whole genome sequence information. Currently, no study has been performed to manipulate metabolic pathways using CRISPR/Cas9. In this study, the type II CRISPR/SpCas9 system was used to knock out, via nonhomologous end-joining genome repair, the 4'OMT2 in opium poppy (Papaver somniferum L.), a gene which regulates the biosythesis of benzylisoquinoline alkaloids (BIAs). For sgRNA transcription, viral-based TRV and synthetic binary plasmids were designed and delivered into plant cells with a Cas9 encoding-synthetic vector by Agrobacterium-mediated transformation. InDels formed by CRISPR/Cas9 were detected by sequence analysis. Our results showed that the biosynthesis of BIAs (e.g. morphine, thebaine) was significantly reduced in the transgenic plants suggesting that 4'OMT2 was efficiently knocked-out by our CRISPR-Cas9 genome editing approach. In addition, a novel uncharacterized alkaloid was observed only in CRISPR/Cas9 edited plants. Thus, the applicabilitiy of the CRISPR/Cas9 system was demonstrated for the first time for medicinal aromatic plants by sgRNAs transcribed from both synthetic and viral vectors to regulate BIA metabolism and biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.